A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

This research is being conducted to asses if HT-6184 is effective in the treatment of Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia. The study includes a 28-day Screening Period followed by a 16- or 32-week Treatment Period. Participants will be monitored at each cycle for drug tolerance, safety, and hematological response. A response assessment will occur after 16 weeks of study treatment.

NCT Number	NCT07052006
Lead Sponsor	Halia Therapeutics, Inc.
Conditions	Myelodysplastic Syndrome, Anemia in Myelodysplastic Syndromes
Enrollment	37 participants
Start Date	2023-12-09
Primary Completion	2026-01-08 (estimated)
Study Completion	2026-08-14 (estimated)
Updated on ClinicalTrials.gov	2026-08-04